• TapImmune Inc., of Seattle, said the Mayo Clinic received investigational new drug application allowance for a Phase I trial of the company's HER-2/neu vaccine in breast cancer patients who finished standard Herceptin (trastuzumab, Roche AG)-based therapy and are at high risk of disease recurrence. The primary endpoints will be safety and immunogenicity. TapImmune is sponsoring the study and has an exclusive option to license the antigen technology at the end of Phase I.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter